Navigation Links
Head and Neck Cancer Vaccine Targets Proteins to Create Immune Response

Researchers have developed a vaccine strategy for head and neck cancer that targets multiple peptides (parts of proteins) to activate the immune system// to attack tumors.

The researchers created the vaccine to target a tumor suppressor gene called p53, which is mutated in most cancers and associated with poor clinical outcomes. Previous research has determined that mutated p53 also expresses unaltered, or "wild-type," p53 peptides in tumors. When presented on dendritic cells, these wild-type p53 peptides may induce an immune response to strengthen the body's natural defenses against cancer and decrease the chance of cancer recurrence and the formation of secondary tumors.

"The key to our strategy is to select those p53 peptides that can best activate the immune system and induce it to produce immune cells able to recognize and eliminate the tumor," said Theresa Whiteside, Ph.D., who in collaboration with Albert DeLeo, Ph.D., directed the study. Both investigators are professors of pathology and immunology at the University of Pittsburgh School of Medicine. "Through animal models and human cells in culture, we have found that this strategy is very effective at stimulating T cells into action," said Dr. Whiteside, who also directs UPCI's Immunologic Monitoring and Cellular Products Laboratory. According to Dr. DeLeo, the vaccine based on these findings also could be relevant to other types of cancer given that the loss of p53 function is a common feature across many cancers.

The vaccine is based on three peptides derived from p53 that target killer T cells and helper T cells. Although killer T cells directly destroy tumor cells, they are assisted by helper T cells that secrete small proteins called cytokines to regulate or "help" the immune response.

Given that the proof of principle for the vaccine has been determined, a phase I clinical trial of the vaccine has begun at the University of Pittsburgh Cancer Institut e to assess its safety in head and neck cancer patients.

Head and neck cancer accounts for about 5 percent of all newly diagnosed cancers in the United States. More than two-thirds of head and neck cancer patients have a locally advanced stage when diagnosed and have a poor five-year survival rate even after treatment.

Source-Eurekalert
'"/>




Related medicine news :

1. Fibroids unlikely to Turn Cancerous
2. Virus Level could Predict Cervical Cancer Risk
3. Cancer Doctors Okays Controversial Prostate Therapy
4. Potential New Cancer Gene Identified
5. Consensus on "Combination Therapy" for Breast Cancer
6. Cancers of Colon & Rectum linked to Cigarette Smoking
7. Life Saving Cancer Drugs – From Chicken! Possible Says Dolly’ Creatos
8. The Cancer Rumour mill working over time
9. Cancer drugs in development nearly doubled since 1995
10. Radioactive Seeds used in Prostate Cancer treatment can migrate with the body
11. Cancer patients turning to Internet for information
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/24/2017)... ... ... Only two months after the official release of The Private Collection – Edition ... has initiated a second print-run of its lavish luxury travel coffee table book. ... weighs in at more than six kilos, retails at EUR 1,000 per copy and ...
(Date:2/24/2017)... ... February 24, 2017 , ... An in-depth computational analysis ... University of Pittsburgh points to eight genes that may explain why susceptibility to one ... the results of a study published today in the journal npj Schizophrenia. , ...
(Date:2/24/2017)... ... February 24, 2017 , ... The Smart Machine Age is ... University predict that 47 percent of all jobs in the United States may be ... “successful.” The day of the aggressive know-it-all who steamrolls over colleagues is drawing to ...
(Date:2/24/2017)... (PRWEB) , ... February 24, 2017 , ... ... and hearing disabilities, it is so critically important that we all are aware ... That is why Mediaplanet is proud to announce the launch of its newest ...
(Date:2/24/2017)... ... February 24, 2017 , ... The narrative in “ Signal 8: An Australian ... account of his paramedic experiences. Schanssema describes the tragedies he saw, as well as ... overcome them. , Schanssema, initially unsure of the career path he wanted to take, ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... , Feb. 23, 2017 Report analyzes the ... provides separate comprehensive analytics for the US, Canada ... , Asia-Pacific , Latin ... forecasts are provided for the period 2015 through 2022. Also, ... data and analytics are derived from primary and secondary research. ...
(Date:2/24/2017)... 2017  Directors from Pharma To Market Pty Ltd and Ador ... resulting in the founding of Pharma To Market Pte Ltd, based ... are pleased to announce their expansion into Asia ... . The company are delighted to appoint Joelle Chia ... Singapore based entity. Joelle brings with her an ...
(Date:2/24/2017)... , Feb. 23, 2017  The particle counters ... by 2021 from USD 275.9 million in 2016, ... the full report: http://www.reportlinker.com/p04718602-summary/view-report.html ... on pharmaceutical R&D, and growth in manufacturing industries ... market growth for particle counters. On the other ...
Breaking Medicine Technology: